Emerging risk factors and markers of CKD progression
|
|
- Grant Phelps
- 5 years ago
- Views:
Transcription
1 Emerging risk factors and markers of CKD progression Florian Kronenberg Innsbruck Medical University, Division of Genetic Epidemiology
2 CKD: Relevance of the problem
3 Initiation and progression of CKD Traditional progression factors or markers: Initiating factors: Age Gender Ethnicity Family history of CKD Diabetes mellitus Metabolic syndrome Hyperfiltration states High normal urinary albumin excretion Dyslipidemia Nephrotoxins Primary kidney disease Urological disorders Cardiovascular disease Chronic Kidney Disease Emerging progression factors or markers:? Progression GFR decline ESRD Nature Rev. Nephrol. 5:677-89, 2009
4
5
6 Definition of CKD progression Surrogates of GFR slope Doubling of baseline serum creatinine level Need of renal replacement therapy (dialysis and/or transplantation) Particular relative increase from baseline serum creatinine level Yearly or monthly decline in GFR GFR reduction to 50% of baseline Graft loss Indices of renal damage Worsening of proteinuria Appearance of albuminuria in patients with diabetes
7
8 Mild to Moderate Kidney Disease Study 227 patients with primary non-diabetic CKD Patients with nephrotic syndrome excluded Recruited 1996/97 Age 46 ± 13 years Iohexol clearance at baseline: average GFR 64 ± 39 ml/min Followed for 7 years Endpoint: doubling of serum creatinine and/or ESRD 177 completed follow-up 65 reached endpoint (36 Crea-doubling, 29 ESRD)
9 ADMA: Asymetric Dimethylarginine Potent and long-lasting endogenous inhibitor of NO synthase less NO production NO is a potent vasodilatator and regulator of the vascular tone and blood flow Kidney is the main site of ADMA removal ADMA markedly increased in renal patients High ADMA levels related to atherosclerotic complications
10 ADMA: Biochemical Pathway 20% Renal excretion Proteins with ADMA residues ADMA L-arginine NO synthase LDL cholesterol Homocysteine Hyperglycemia Hypertension Smoking Inflammation Aging D D A H 80% Dimethlyamine + Citrulline DDAH, dimethylarginine dimethylaminehydrolase NO Consequences of decreased NO Decreased renal plasma flow Increased renovascular resistance Increased blood pressure Endothelial damage Progression of chronic kidney disease Nature Rev. Nephrol. 5:677-89, 2009
11 ADMA and progression of CKD: MMKD-Study Cox regression: HR 1.47 (95% CI ) for 0.1 µm/l increase Fliser et al.: J.Am.Soc.Nephrol. 16: , 2005
12 ADMA and progression of CKD and death n=29 n=31 ADMA <0.76 µm/l ADMA <0.76 µm/l ADMA 0.76 µm/l ADMA 0.76 µm/l n=131, age 71±11yrs, GFR 8-77 ml/min, follow-up 27 mos Ravani et al.: J.Am.Soc.Nephrol. 16: , 2005
13 ADMA and progression of CKD Hanai et al: NDT 24:1884-8, 2009: Progression of diabetic nephropathy 37 of 225 patients with T2DM Lajer et al: Diabetes care 31:747-52, 2008: 397 patients with T1DM and nephropathy Yearly decline in GFR p<0.001
14 Calcium-phosphate metabolism Progression of CKD in animal models: High phosphate High PTH Lack of active vitamin D Ca-Ph metabolism and progression of CKD in humans: High phosphate (5 of 5 studies) and high Ca*Ph (3 of 4 studies) High PTH levels (2 of 2 studies) Fibroblast Growth Factor 23 (FGF23): Recently identified phosphatonin Regulator of phosphate balance Under physiological conditions: high phosphate load results in increased FGF23 secretion and phosphaturia
15 Calcium-phosphate metabolism and progression Results from the MMKD Study Non-progressors (n=112) Progressors (n=65) p-value FGF 23 c-terminal (ru/ml) 92 ± ± 394 <0.001 FGF 23 intact (pg/ml) 35 ± ± 70 <0.001 Phosphate (mmol/l) 1.04 ± ± 0.27 <0.001 Ca x P product (mmol 2 /L 2 ) 2.46 ± ± 0.65 <0.001 Parathormone (pmol/l) 6.5 ± ± 20.0 <0.001 Fliser, Kollerits et al.: J.Am.Soc.Nephrol. 18:2600-8, 2007
16 Multiple Cox regression analysis Adjusted for age, sex, GFR, proteinuria and the other variables of this table Variable (increment) HR (95% CI) p Phosphate (0.1 mmol/l) ( ) Ca x P product (0.1 mmol 2 /L 2 ) ( ) Parathormone (1 pmol/l) ( ) FGF23 c-terminal (10 ru/ml) ( ) FGF23 intact (10 pg/ml) ( ) Fliser, Kollerits et al.: J.Am.Soc.Nephrol. 18:2600-8, 2007
17 Multiple Cox regression analysis Adjusted for age, sex, GFR, proteinuria and the other variables of this table Variable (increment) HR (95% CI) p Phosphate (0.1 mmol/l) ( ) Ca x P product (0.1 mmol 2 /L 2 ) ( ) Parathormone (1 pmol/l) ( ) FGF23 c-terminal (10 ru/ml) ( ) FGF23 intact (10 pg/ml) ( ) FGF23 c-terminal +250 ru/ml 35% increased risk (adjusted for age, sex, GFR and proteinuria) Fliser, Kollerits et al.: J.Am.Soc.Nephrol. 18:2600-8, 2007
18 FGF23 and progression of CKD in MMKD Progression 10% 60% Fliser, Kollerits et al.: J.Am.Soc.Nephrol. 18:2600-8, 2007
19 Vitamin D and CKD progression 168 newly referred patients with CKD stages 2-5 Follow-up median 57 mos. Endpoint: dialysis treatment in 48 cases 10 ng/ml increase in 25- hydroxy vitamin D level was associated with a 40% decrease in hazard ratio for CKD progression Ravani et al.: Kidney Int. 75:88-95, 2009
20 Adiponectin Produced in adipocytes Central role in glucose and lipid metabolism (insulin sensitizer) An anti-inflammatory, anti-atherosclerotic and vasculo-protective cytokine A large number of studies showed an association between low adiponectin levels and negative outcomes Adiponectin is elevated in patients with kidney impairment
21 High adiponectin and CKD progression Study Study population End points Specific observation Followup MMKD Study nondiabetic patients with primary CKD Doubling of serum creatinine and / or ESRD (n=65) Observed only in men Median 53 mos. EURAGEDIC Case-Control Study patients with T1DM with nephropathy Dialysis or kidney transplantation (n=40) Median 8.1 yrs. Finish Diabetic Nephropathy Study patients with T1DM Progression to ESRD (83/296 patients with macroalbuminuria) No association in patients with normo- or microalbuminuria Mean 5 yrs. Kollerits et al.: Kidney Int. 71: , 2007 Jorsal et al.: Kidney Int. 74:649-54, 2008 Saraheimo et al.: Diabetes care 31:1165-9, 2008
22 Adiponectin association "reshaped" High adiponectin in other studies predicted lower risk for cardiovascular events in ESRD (Zoccali et al. 2002) mortality in CKD 3 and 4 in the MDRD Study (Menon et al. 2006) mortality in patients with CHF (Kistorp et al. 2005) all-cause and CVD mortality in CAD patients (Pilz et al. 2006) and several other studies
23 Adiponectin association "reshaped" High adiponectin in other studies predicted lower risk for cardiovascular events in ESRD (Zoccali et al. 2002) mortality in CKD 3 and 4 in the MDRD Study (Menon et al. 2006) mortality in patients with CHF (Kistorp et al. 2005) all-cause and CVD mortality in CAD patients (Pilz et al. 2006) and several other studies The association of adiponectin might turn in the opposite direction in the presence of severe disease conditions A compensatory attempt to attenutae endothelial and vascular damage? Adiponectin resistance?
24 Apolipoprotein A-IV and CKD progression Activates LPL and LCAT MMKD Study Median = 26 mg/dl Stimulates cholesterol efflux from peripheral cells Reverse cholesterol transport Antioxidative properties Strong association with kidney function p< Boes et al.: J.Am.Soc.Nephrol. 17:528-36, 2006
25 Apolipoprotein A-IV and CKD progression Activates LPL and LCAT MMKD Study Median = 26 mg/dl Stimulates cholesterol efflux from peripheral cells Reverse cholesterol transport Antioxidative properties Strong association with kidney function p< ApoA-IV +10 mg/dl 60% increase in risk of CKD progression Boes et al.: J.Am.Soc.Nephrol. 17:528-36, 2006
26 Natriuretic peptides and CKD progression: MMKD Potent hypotensive, diuretic and natriuretic peptides involved in maintaining cardiovascular and renal homeostasis Produced in the kidney Increased concentrations associated with CVD and renal disease Renoprotective properties compensatory increase in CKD Variable (1 SD increment) HR (95% CI) p-value NT-pro BNP (527 ng/l) 1.15 ( ) 0.13 A-type natriuretic peptide (131 pmol/l) 2.11 ( ) <0.001 Adrenomedullin (0.42 nmol/l) 2.60 ( ) <0.001 Adjusted for age, sex, GFR, and proteinuria Dieplinger et al.: Kidney Int. 75:408-14, 2009
27 Calculating the gain in information GFR Proteinuria ADMA FGF23 ANP Adrenomedullin NT-proBNP ApoA-IV Problem of correlation of variables (multicollinearity)
28 MMKD Study: Comparison of parameters adjusted for age, sex, GFR and proteinuria Nature Rev. Nephrol. 5:677-89, 2009
29
30
31 Genomewide association studies (GWAS) 23 pairs of chromosomes Genotyping of up to 1 million single nucleotide polymorphisms (SNPs) in thousands of persons Phenotype (e.g. CKD, CKD progression, GFR) Association analysis
32 Genetic factors for CKD progression Advantages of polymorphisms: Stability: inherited at conception and do not change with disease Causality is likely (no reverse causation) Gene ADIPOQ (adiponectin) Strong association explains 8% Intermediate phenotype Plasma adiponectin concentrations Strong association explains 10% Endphenotype Progressive CKD Nature Rev. Nephrol. 5:677-89, 2009
33 Genetic factors for CKD progression Advantages of polymorphisms: Stability: inherited at conception and do not change with disease Causality is likely (no reverse causation) Mendelian Randomization Gene ADIPOQ (adiponectin) Strong association explains 8% Intermediate phenotype Plasma adiponectin concentrations Strong association explains 10% Endphenotype Progressive CKD Weak association explains 0.8% (0.08 x 0.10) Nature Rev. Nephrol. 5:677-89, 2009
34 Genetic factors for CKD progression Advantages of polymorphisms: Stability: inherited at conception and do not change with disease Causality is likely (no reverse causation) Mendelian Randomization Gene ADIPOQ (adiponectin) Strong association explains 8% Intermediate phenotype Plasma adiponectin concentrations Strong association explains 10% Endphenotype Progressive CKD Requires large sample sizes Weak association explains 0.8% (0.08 x 0.10) Nature Rev. Nephrol. 5:677-89, 2009
35 Genetic factors for CKD progression Advantages of polymorphisms: Stability: inherited at conception and do not change with disease Causality is likely (no reverse causation) Mendelian Randomization No reverse causation Gene ADIPOQ (adiponectin) Strong association explains 8% Intermediate phenotype Plasma adiponectin concentrations Strong association explains 10% Endphenotype Progressive CKD Requires large sample sizes Weak association explains 0.8% (0.08 x 0.10) Nature Rev. Nephrol. 5:677-89, 2009
36 GWAS on kidney function Meta-analysis: CKDGen consortium 20 population-based cohort studies >90,000 persons 20 new genetic loci for renal function and chronic kidney disease Uromodulin (UMOD): codes for Tamm-Horsefall protein Association with prevalent and incident CKD and egfr creatinine Rare mutations cause monogenic forms of kidney diseases Köttgen et al.: Nat.Genet. (online)
37 GWAS on kidney function Meta-analysis: CKDGen consortium 20 population-based cohort studies >90,000 persons 20 new genetic loci for renal function and chronic kidney disease Uromodulin (UMOD): codes for Tamm-Horsefall protein Association with prevalent and incident CKD and egfr creatinine Rare mutations cause monogenic forms of kidney diseases Köttgen et al.: Nat.Genet. (online)
38 Future developments Combination of GWAS and metabolomics: Gieger et al.: PLoS Genetics 2008 Illig et al.: Nature Genetics 2010 Personalized health-care system Nature Rev. Nephrol. 5:677-89, 2009
39 Summary Chronic Kidney Disease Progression GFR decline ESRD Emerging progression factors or markers: (number of studies) They are independent from GFR and proteinuria. Many of them are independent from each other. Some of them might also reflect a cardiorenal syndrome. Large studies are urgently required.
40 The MMKD Study Group Barbara Kollerits Eva Boes Paul König Karl Lhotta Ulrich Neyer Danilo Fliser Jan Kielstein Iris M. Heid Benjamin Dieplinger Peter Riegler Eberhard Ritz Gerhard Müller Günter Kraatz Johannes Mann Werner Riegel Vedat Schwenger Katharina-Susanne Spanaus Arnold von Eckardstein Renal Units: Project Support: Innsbruck, Feldkirch, Greifswald, Heidelberg, München-Schwabing, Göttingen, Homburg/Saar, Bozen GEN-AU (Austrian Genome Project) Austrian Science Fund, Austrian National Bank Austrian Academy of Sciences Austrian Heart Fund Else Kröner-Fresenius Stiftung
JOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHomoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study
Homoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study Christiane Drechsler 1, Barbara Kollerits 2, Andreas Meinitzer 3, Winfried März 4, Eberhard
More informationEvaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSOME NOVEL BIOMARKERS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
SOME NOVEL BIOMARKERS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE Dept. of nephrology, Clinic for internal medicine University Medical Centre Maribor Faculty of Medicine, University
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationBiomarkers in chronic kidney disease: a review
review http://www.kidney-international.org & 2011 International Society of Nephrology Biomarkers in chronic kidney disease: a review Robert G. Fassett 1,2,3, Sree K. Venuthurupalli 3,4, Glenda C. Gobe
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationSympathetic nervous system and NO in CKD. Francesca Mallamaci
Sympathetic nervous system and NO in CKD Francesca Mallamaci Go AS, New Engl J Med. 351: 1296; 24 1.12.295 individuals, follow up 2.8 yea risk factors peculiar to CKD Old age Relative Risk (fully independent)
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationAsymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study
Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study Danilo Fliser,* Florian Kronenberg, Jan T. Kielstein,* Christian Morath, Stefanie M. Bode-Böger,
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationDiabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationDiabetic Nephropathy
Diabetic Nephropathy Outline Introduction of diabetic nephropathy Manifestations of diabetic nephropathy Staging of diabetic nephropathy Microalbuminuria Diagnosis of diabetic nephropathy Treatment of
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationBiomarkers in risk prediction of heart and kidney disease
Biomarkers in risk prediction of heart and kidney disease Winfried März Medizinische Universität Graz, Medizinische Klinik V Medizinische Fakultät Mannheim, Universität Heidelberg, Synlab Akademie, Mannheim
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationApolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study
Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study Eva Boes,* Danilo Fliser, Eberhard Ritz, Paul König, Karl Lhotta, Johannes F.E. Mann, Gerhard
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationAn update on the obesity epidemics in CKD and in ESRD. Does it really matter?
EURECA-m 2011 An update on cutting-edge Cardiovascular and Renal Medicine themes. An update on the obesity epidemics in CKD and in ESRD. Does it really matter? Francesca Mallamaci BMI>30 25 Ireland 20
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationShihui Fu 1,2, Yi Guo 2, Zhao Zhang 2, Leiming Luo 1* and Ping Ye 1*
Fu et al. BMC Nephrology (2018) 19:93 https://doi.org/10.1186/s12882-018-0888-3 RESEARCH ARTICLE Single-marker and multi-marker approaches to appraise the relationships between biomarkers and microalbuminuria
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationoriginal article see commentary on page 1272
http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 1272 Lower estimated glomerular filtration rate and higher albuminuria are associated
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationDiabetes and the Cardiorenal Syndrome
Wednesday, November 11, 2015 Diabetes and the Cardiorenal Syndrome Dr. Nancy Haley Clinical Consultant Answers for life. Topics Covered Overview The Stats Cardiorenal Syndrome Guidelines Case Studies What
More informationEffects of Lowering LDL Cholesterol on Progression of Kidney Disease
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen,
More informationRENAL GRAND ROUNDS. Vitamin D- Beyond the bone. Dr Krishna Pakkivenkata. 9 th April 2010.
RENAL GRAND ROUNDS Vitamin D- Beyond the bone Dr Krishna Pakkivenkata. 9 th April 2010. Brief history Secosteroid. 1920 s-exposure to sunlight prevented rickets. 1936- structure of Vit D was discovered.
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationTransforming Diabetes Care
Transforming Diabetes Care Diabetic Kidney Disease: Prevention, Detection and Treatment Alexis Chettiar, ACNP-BC, PhD(c) 1 Polling Question - 1 What is your role as a healthcare provider? a) Dietitian
More informationDevelopment of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study
J Am Soc Nephrol 14: 641 647, 2003 Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study JOHANNES F. E. MANN, HERTZEL C. GERSTEIN, QI-LONG YI, EVA M.
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationProf. Michel Jadoul Cliniques universitaires St-Luc Université Catholique de Louvain Brussels, Belgium. Slide 1
Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol? Michel Jadoul, Brussels, Belgium Chairs: Pablo Urena Torres, Saint-Ouen, France Carmine Zoccali, Reggio Calabria, Italy
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationChronic kidney disease-what can you do and when to refer?
Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More information